Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Subbiah V, et al. Among authors: trigo j. Lung Cancer. 2020 Dec;150:90-96. doi: 10.1016/j.lungcan.2020.10.003. Epub 2020 Oct 10. Lung Cancer. 2020. PMID: 33096421 Free article. Clinical Trial.
Tumor markers at the time of recurrence in patients with germ cell tumors.
Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P, Esteban E, Salazar R, López-López JJ, Cortés-Funes H. Trigo JM, et al. Cancer. 2000 Jan 1;88(1):162-8. doi: 10.1002/(sici)1097-0142(20000101)88:1<162::aid-cncr22>3.0.co;2-v. Cancer. 2000. PMID: 10618619
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Heymach JV, et al. Among authors: trigo jm. J Clin Oncol. 2008 Nov 20;26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20. J Clin Oncol. 2008. PMID: 18936474 Clinical Trial.
SEOM guidelines for the management of non-small-cell lung cancer (NSCLC).
Felip E, Garrido P, Trigo JM, López-Brea M, Paz-Ares L, Provencio M, Isla D; Spanish Society of Medical Oncology. Felip E, et al. Among authors: trigo jm. Clin Transl Oncol. 2009 May;11(5):284-9. doi: 10.1007/s12094-009-0356-4. Clin Transl Oncol. 2009. PMID: 19451061
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J. Bellmunt J, et al. Among authors: trigo jm. Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15. Lancet Oncol. 2010. PMID: 20163987 Clinical Trial.
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R. Salazar F, et al. Among authors: trigo jm. Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11. Lung Cancer. 2011. PMID: 20705357
Recommendations for the optimal management of early and advanced urothelial carcinoma.
Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J. Castellano D, et al. Among authors: trigo jm. Cancer Treat Rev. 2012 Aug;38(5):431-41. doi: 10.1016/j.ctrv.2011.10.004. Epub 2011 Nov 23. Cancer Treat Rev. 2012. PMID: 22116017 Review.
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D. De Castro J, et al. Among authors: trigo jm. Clin Transl Oncol. 2017 Feb;19(2):219-226. doi: 10.1007/s12094-016-1527-8. Epub 2016 Jul 1. Clin Transl Oncol. 2017. PMID: 27371031
295 results